A phosphatidylinositol 3-Kinase-Pax3 axis regulates Brn-2 expression in melanoma

Molecular and Cellular Biology

Volumn 32, Issue 22, 2012, Pages 4674-4683

  Bonvin, Elise ^a,b   Falletta, Paola ^a   Shaw, Heather ^a   Delmas, Veronique ^b   Goding, Colin R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRN2; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ARTICLE; CANCER INVASION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHATIDYLINOSITOL 3-KINASES; POU DOMAIN FACTORS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 84868676821     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01067-12     Document Type: Article

References (58)

1. Arnheiter H. 2010. The discovery of the microphthalmia locus and its gene, Mitf. Pigment Cell Melanoma Res. 23:729 -735.
2. Arozarena I, et al. 2011. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19:45-57.
3. Aziz SA, et al. 2009. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin. Cancer Res. 15:3029 -3036.
4. Boyle GM, et al. 2011. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 24:525-537.
5. Carreira S, et al. 2005. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433:764 -769.
6. Carreira S, et al. 2006. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20:3426 -3439.
7. Chalepakis G, Goulding M, Read A, Strachan T, Gruss P. 1994. Molecular basis of splotch and Waardenburg Pax-3 mutations. Proc. Natl. Acad. Sci. U. S. A. 91:3685-3689.
8. Cheli Y, et al. 2011. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30:2307-2318.
9. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. 2010. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 23:27- 40.
10. Christova T, Mojtahedi G, Hamel PA. 2010. Lymphoid enhancer factor-1 mediates loading of Pax3 to a promoter harbouring lymphoid enhancer factor-1 binding sites resulting in enhancement of transcription. Int. J. Biochem. Cell Biol. 42:630-640.
11. Cook AL, Sturm RA. 2008. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res. 21:611- 626.
12. Corry GN, Underhill DA. 2005. Pax3 target gene recognition occurs through distinct modes that are differentially affected by diseaseassociated mutations. Pigment Cell Res. 18:427- 438.
13. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. 2006. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Investig. Dermatol. 126:1660 -1663.
14. Dankort D, et al. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41:544 -552.
15. Davies H, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949 -954.
16. Delmas V, et al. 2007. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21:2923-2935.
17. Eisen T, Easty DJ, Bennett DC, Goding CR. 1995. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11: 2157-2164.
18. Galibert M-D, Yavuzer U, Dexter TJ, Goding CR. 1999. Pax3 and regulation of the melanocyte-specific TRP-1 promoter. J. Biol. Chem. 274: 26894-26900.
19. Goodall J, et al. 2008. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 68:7788 -7794.
20. Goodall J, et al. 2004. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol. Cell. Biol. 24:2915-2922.
21. Goodall J, et al. 2004. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24:2923-2931.
22. Govindarajan B, et al. 2007. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Investig. 117: 719-729.
23. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
24. Heppner GH. 1984. Tumor heterogeneity. Cancer Res. 44:2259 -2265.
25. Hoek K, Goding CR. 2010. Cancer stem cells versus phenotype switching in melanoma. Pigment Cell Melanoma Res. 23:746 -759.
26. Hoek KS, et al. 2008. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68:650-656.
27. Hoek KS, et al. 2006. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19:290 -302.
28. Hsieh MJ, Yao YL, Lai IL, Yang WM. 2006. Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1. Biochem. Biophys. Res. Commun. 349: 573-581.
29. Khaled M, et al. 2003. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J. Investig. Dermatol. 121:831- 836.
30. Kobi D, et al. 2010. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res. 23:404-418.
31. Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D. 2008. Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res. 21:627- 645.
32. Lang D, et al. 2005. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433:884-887.
33. Lee M, Goodall J, Verastegui C, Ballotti R, Goding CR. 2000. Direct regulation of the microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. J. Biol. Chem. 275:37978 -37983.
34. Lopez-Bergami P. 2011. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 24:902-921.
35. Madhunapantula SV, Robertson GP. 2009. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22:400-419.
36. Marusyk A, Polyak K. 2010. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805:105-117.
37. Mayanil CS, et al. 2006. Regulation of murine TGFbeta2 by Pax3 during early embryonic development. J. Biol. Chem. 281:24544 -24552.
38. Medic S, Rizos H, Ziman M. 2011. Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem. Biophys. Res. Commun. 411:832- 837.
39. Michailidou C, et al. 2009. Dissecting the roles of Raf- and PI3Ksignalling pathways in melanoma formation and progression in a zebrafish model. Dis. Model Mech. 2:399-411.
40. Monterrubio M, Mellado M, Carrera AC, Rodriguez-Frade JM. 2009. PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion. Biochem. Biophys. Res. Commun. 388:199 -204.
41. Nogueira C, et al. 2010. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29:6222- 6232.
42. Omholt K, Krockel D, Ringborg U, Hansson J. 2006. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 16:197-200.
43. Pinner S, et al. 2009. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 69:7969 -7977.
44. Plummer RS, et al. 2008. PAX3 expression in primary melanomas and nevi. Mod. Pathol. 21:525-530.
45. Rubinfeld B, et al. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790 -1792.
46. Shull AY, et al. 2012. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 7:e43369. doi:10.1371/journal. pone.0043369.
47. Stahl JM, et al. 2004. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64:7002-7010.
48. Takeda K, et al. 2000. Induction of melanocyte-specific microphthalmiaassociated transcription factor by Wnt-3a. J. Biol. Chem. 275:14013- 14016.
49. Thomson JA, et al. 1995. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11:690 -700.
50. Thurber AE, et al. 2011. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30:3036 -3048.
51. Tsao H, Zhang X, Benoit E, Haluska FG. 1998. Identification of PTEN/ MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-3402.
52. Visvader JE, Lindeman GJ. 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8:755-768.
53. Watanabe A, Takeda K, Ploplis B, Tachibana M. 1998. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat. Genet. 18:283-286.
54. Wellbrock C, et al. 2008. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3:e2734. doi: 10.1371/journal.pone.0002734.
55. Wu H, Goel V, Haluska FG. 2003. PTEN signaling pathways in melanoma. Oncogene 22:3113-3122.
56. Yavuzer U, Goding CR. 1994. Melanocyte-specific gene expression: role of repression and identification of a melanocyte-specific factor, MSF. Mol. Cell. Biol. 14:3494 -3503.
57. Yoon SO, Shin S, Lee HJ, Chun HK, Chung AS. 2006. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/ Akt-dependent matrix metalloproteinase-9 expression. Mol. Cancer Ther. 5:2666 -2675.
58. Zhou XP, et al. 2000. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157:1123-1128.